TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)
$36.44 -1.18 (-3.1366%)
Analysed TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) News Sources
AUPH Stock Rallies 6% After-Hours — Here’s Why
19-08-2026
stocktwits.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
20-08-2026
yahoo.com
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
20-08-2026
yahoo.com
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
25-08-2026
yahoo.com
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
28-08-2026
yahoo.com
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
28-08-2026
yahoo.com
BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals
28-08-2026
yahoo.com
Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value
30-08-2026
yahoo.com
Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing
30-08-2026
yahoo.com
What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
30-08-2026
yahoo.com
What is the current price of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The current price of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is $36.44.
TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) absolute price change since previous trading day?
The absolute price change of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) since the previous trading day is $-1.18.
TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) percentage price change since previous trading day?
The percentage price change of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) since the previous trading day is -3.1366%.
What is the most recent average sentiment score for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The most recent average sentiment score for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is 61 out of 100.
What is the most recent average sentiment for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The most recent sentiment for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is .
SEC-8K** Filing Available For TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.